**

A. Mechanical/Hydraulic Incontinence Control Devices

**

Mechanical/hydraulic incontinence control devices are accepted as safe and
effective in the management of urinary incontinence in patients with permanent
anatomic and neurologic dysfunctions of the bladder. This class of devices
achieves control of urination by compression of the urethra. The materials
used and the success rate may vary somewhat from device to device. Such a
device is covered when its use is reasonable and necessary for the individual
patient.

**

B. Collagen Implant

**

A collagen implant, which is injected into the submucosal tissues of the
urethra and/or the bladder neck and into tissues adjacent to the urethra, is a
prosthetic device used in the treatment of stress urinary incontinence
resulting from intrinsic sphincter deficiency (ISD). ISD is a cause of stress
urinary incontinence in which the urethral sphincter is unable to contract and
generate sufficient resistance in the bladder, especially during stress
maneuvers.

Prior to collagen implant therapy, a skin test for collagen sensitivity must
be administered and evaluated over a 4 week period.

In male patients, the evaluation must include a complete history and physical
examination and a simple cystometrogram to determine that the bladder fills
and stores properly. The patient then is asked to stand upright with a full
bladder and to cough or otherwise exert abdominal pressure on his bladder. If
the patient leaks, the diagnosis of ISD is established.

In female patients, the evaluation must include a complete history and
physical examination (including a pelvic exam) and a simple cystometrogram to
rule out abnormalities of bladder compliance and abnormalities of urethral
support. Following that determination, an abdominal leak point pressure (ALLP)
test is performed. Leak point pressure, stated in cm H2O, is defined as the
intra-abdominal pressure at which leakage occurs from the bladder (around a
catheter) when the bladder has been filled with a minimum of 150 cc fluid. If
the patient has an ALLP of less than 100 cm H2O, the diagnosis of ISD is
established.

To use a collagen implant, physicians must have urology training in the use of
a cystoscope and must complete a collagen implant training program.

Coverage of a collagen implant, and the procedure to inject it, is limited to
the following types of patients with stress urinary incontinence due to ISD:

  * Male or female patients with congenital sphincter weakness secondary to conditions such as myelomeningocele or epispadias;
  * Male or female patients with acquired sphincter weakness secondary to spinal cord lesions;
  * Male patients following trauma, including prostatectomy and/or radiation; and
  * Female patients without urethral hypermobility and with abdominal leak point pressures of 100 cm H2O or less.

Patients whose incontinence does not improve with 5 injection procedures (5
separate treatment sessions) are considered treatment failures, and no further
treatment of urinary incontinence by collagen implant is covered. Patients who
have a reoccurrence of incontinence following successful treatment with
collagen implants in the past (e.g., 6-12 months previously) may benefit from
additional treatment sessions. Coverage of additional sessions may be allowed
but must be supported by medical justification.